Forte Biosciences (FBRX) Operating Leases (2019 - 2020)
Forte Biosciences (FBRX) reported Operating Leases of $3.9 million for Q1 2020, down 59.07% year-over-year from $9.6 million in Q2 2019, and down 2.86% quarter-over-quarter from $4.0 million in Q4 2019.
Forte Biosciences (FBRX) Operating Leases (2019 - 2020) Analysis & Trends
Forte Biosciences (FBRX) has 2 years of Operating Leases data on file, last reported at $3.9 million in Q1 2020.
- Operating Leases for Q1 2020 came in at $3.9 million, down 59.07% year-over-year; the trailing twelve-month figure through Mar 2020 was $3.9 million (down 59.07% YoY), and the FY2019 annual result was $4.0 million, changed N/A from the prior year.
- Operating Leases retreated to $3.9 million in Q1 2020 per FBRX's latest filing, from $4.0 million in the prior quarter.
- Over five years, Operating Leases peaked at $9.6 million in Q1 2019 and troughed at $3.9 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 3.91 Mn |
| Dec 31, 2019 | 4.03 Mn |
| Sep 30, 2019 | 9.12 Mn |
| Jun 30, 2019 | 9.36 Mn |
| Mar 31, 2019 | 9.56 Mn |